HIV causes a chronic infection characterized by depletion of CD4(+) T lymphocytes and the development of opportunistic infections. Despite drugs that inhibit viral spread, HIV infection has been difficult to cure because of uncharacterized reservoirs of infected cells that are resistant to highly active antiretroviral therapy (HAART) and the immune response. Here we used CD34(+) cells from infected people as well as in vitro studies of wild-type HIV to show infection and killing of CD34(+) multipotent hematopoietic progenitor cells (HPCs). In some HPCs, we detected latent infection that stably persisted in cell culture until viral gene expression was activated by differentiation factors. A unique reporter HIV that directly detects latently infected cells in vitro confirmed the presence of distinct populations of active and latently infected HPCs. These findings have major implications for understanding HIV bone marrow pathology and the mechanisms by which HIV causes persistent infection.
HIV causes a chronic infection characterized by depletion of CD4(+) T lymphocytes and the development of opportunistic infections. Despite drugs that inhibit viral spread, HIV infection has been difficult to cure because of uncharacterized reservoirs of infected cells that are resistant to highly active antiretroviral therapy (HAART) and the immune response. Here we used CD34(+) cells from infected people as well as in vitro studies of wild-type HIV to show infection and killing of CD34(+) multipotent hematopoietic progenitor cells (HPCs). In some HPCs, we detected latent infection that stably persisted in cell culture until viral gene expression was activated by differentiation factors. A unique reporter HIV that directly detects latently infected cells in vitro confirmed the presence of distinct populations of active and latently infected HPCs. These findings have major implications for understanding HIV bone marrow pathology and the mechanisms by which HIV causes persistent infection.
Despite the host immune response and treatment with highly active
antiretroviral therapy (HAART), HIV causes a persistent infection. Viral persistence
is due in part to latent HIV reservoirs in resting CD4+ T cells 1 that do not express viral proteins but can be
induced to active infection by a variety of stimuli. However, recent studies of
viral genetics have revealed that additional reservoirs likely exist 2.Hematopoietic progenitor cells (HPCs) have been considered as a possible
reservoir, but it has been difficult to establish that these cells are infected by
HIV 3-6
because HPCs are difficult to maintain in culture and indirect measurements of
infection may be confounded by contamination with other cell types. Here, we
utilized flow cytometry and recently developed culture conditions 7 that have allowed us to conclude that a
proportion of HPCs become infected following exposure to HIV both in
vivo and in vitro.
RESULTS
HIV infects HPCs
To assess the susceptibility of HPCs to HIV, intracellular Gag expression
was examined using purified bone marrow (BM) CD34+ cells treated with
HIV 89.6ΔEenv89.6 (Fig. 1a). After 3 d in culture, 6% of CD34+ HPCs
expressed intracellular HIV Gag (Fig. 2a,
middle right panel). Antiretroviral treatment blocked Gag expression (Fig. 2a, lower right panel) and experiments
with five other HIVs yielded similar results (Supplementary Fig. 1a).
As previously reported for HIV–infected T cells 8,9, infected
CD34+ cells downmodulated MHC–I (Fig. 2b).
Figure 1
HIV genomes. (a), (b), (c),
(e) and (g) are derived from the molecular
clone p89.6. (d) and (f) have been described
elsewhere and are derived from HXB and NL4–3 11-13. Expressed
viral genes are shown in white, deletions and additions to the genome are
shown in black, and non–functional genes are shaded in gray.
Figure 2
HIV actively infects HPCs, leading to cell death. (a).
Intracellular Gag in BM–derived CD34+ HPCs infected with
HIV 89.6ΔEenv89.6 (Fig. 1a) for 3 d. Gray histograms are isotype controls.
(b) CD34, MHC-I and intracellular Gag expression in
UCB–derived CD34+ HPCs infected with
89.6ΔEenv89.6 for 48 h.
(c) Gag, CD34 and Lin staining in BM–derived
CD34+ HPCs infected with 89.6. (d) Time course
of intracellular Gag expression in UCB–derived CD34+ HPCs
infected with 89.6. (e) Annexin V reactivity in
UCB–derived CD34+ HPCs infected with
89.6ΔEenv89.6 for 48 h. The right
panel shows CD34+Gag− (gray gate and
histograms) and CD34+Gag+ cells (black gate and
histogram).
HPCs are a heterogeneous collection of cells that include multipotent
HPCs and stem cells (HSCs). Multipotent HPCs have a
Lin−CD34+CD133+CD38−
surface phenotype, where “Lin” represents markers of specific
hematopoietic lineages. Following treatment with wild type HIV 89.6 (Fig. 1b), both Lin+ and
Lin− cells expressed intracellular Gag (Fig. 2c).
HIV is cytotoxic to infected HPCs
A time course analysis revealed that Gag+ cells were lost
rapidly in culture (Fig. 2d
and
Supplementary Fig. 1b).
Moreover, infected cells displayed increased annexin V reactivity (Fig. 2e) and a high fraction of
Gag+ cells had light scatter properties of dead cells (Supplementary Fig. 1c).
Cell death required active viral gene expression as transduction of the cells
with a reporter virus (Fig.
1c) pseudotyped with an HIV envelope did not result in
cell loss unless the HIV LTR actively expressed HIV genes (Supplementary Fig.
1d).
Multipotent HPCs are susceptible to HIV infection
To assess the developmental capacity of infected HPCs, we used a
minimal HIV genome (HIV–7SF–GFP, Fig. 1d) pseudotyped with 89.6 Env, which “tagged”
infected cells without causing cell death. Using this system, we found that
a proportion of CD34+ cells were infected (GFP+) [1 to
6% in replicate experiments (e.g. Fig.
3a; initial sort purity shown in
Supplementary Fig.
2a)] and a more primitive subset of these cells
(CD34+CD38−CD133+) had a similar
infection rate (Fig. 3b). Infection of
CD133+ HPCs purified from BM yielded similar results (Supplementary Fig. 2f and
g). These infection rates were comparable to the fraction of
CD34+ cells expressing both HIV co–receptors (Supplementary Fig. 3a and
b).
Figure 3
HIV infects multipotent HPCs. (a) GFP expression in
CD34+ UCB cells infected with
HIV–7SF–GFPenv89.6 for 3 d.
(b) The percentage of
CD133+,CD34+,CD38− cells
expressing GFP 3 d post–infection with
HIV–7SF–GFPenv89.6. Gray
histograms and events represent isotype control staining. (c)
and (e), Colony formation by
GFPCD133+ UCB–derived HPCs
infected with
HIV–7SF–GFPenv89.6(c)
or 89.6–SIΔE–GFPenv89.6
(e). (d) and (f), The relative
number of colonies formed by equal numbers of sorted GFP+ and
GFP−, CD133+ UCBs infected with
HIV–7SF–GFPenv89.6
(d) or
89.6–SIΔE–GFPenv89
(f). (erythroid (CFU–E),
granulocyte–macrophage (CFU–GM), multi–lineage
(CFU–GEMM)).
CD133+ HPCs from UCB infected with
HIV–7SF–GFPenv89.6 generated
GFP+ colonies of erythroid (CFU–E), myeloid
(CFU–M and CFU–GM) and multi–lineage (CFU–GEMM)
origin, demonstrating that HIV can infect multipotent HPCs (Fig. 3c). Quantitation revealed similar
numbers of total colonies from uninfected and infected cells (Fig. 3d). Similar results were obtained
using a full–length HIV reporter
(89.6–SIΔE–SF–GFP, Fig. 1e) that did not express HIV genes because of an LTR
mutation (Fig. 3e,f).
Induction of latent HIV from infected HPCs
To assess latent infection, we asked whether induction of
differentiation induced viral gene expression. Indeed, BM–derived
HPCs (99.5% CD34+, Supplementary Fig. 2b) infected with replication
defective [HIV HXB–ePLAPenvVSV–G (Fig. 1f)] and treated with PMA expressed
the reporter in 12-fold more cells (Fig.
4a) and produced more viral particles (Supplementary Fig.
4a) than the control. BM immunodepleted for CD34+ cells
were not viable under these conditions (Supplementary Fig.
4b).
Figure 4
Induction of HIV from latency. (a) The percentage of BM
CD34+ HPCs (See Supplementary Fig. 2b for initial cell purity)
expressing an HIV marker gene (PLAP) following infection with
HXB–ePLAPenvVSVG plus or minus PMA.
(b) qPCR 14 of
integrated DNA from BM CD34+ cells infected and cultured as in
(a). Pol–minus samples lack polymerase in the first
round. Data are displayed as mean relative amount of integrated HIV DNA
± standard deviation (sd), n = 3. (c)
The percentage of BM–derived CD34+ HPCs (Supplementary Fig.
2c) expressing intracellular Gag following infection with
HXB–ePLAPenv89.6 plus or minus 10 ng
ml−1 PMA. (d) Reverse transcriptase
activity of CD34+ BM HPCs (Supplementary Fig.
2c) infected with HIV 89.6, plus or minus
GM–CSF–TNF–α. The mean ± sd,
n = 3 is shown. Control is BMMC immunodepleted for
CD34. (e) Intracellular Gag expression 14 d
post–infection for BM–derived HPCs infected and cultured as in
(d). (f) CD34 and CD83 expression (right
panels) after 2 weeks in CC110 or GM–CSF–TNF–α.
Isotype–matched controls are shown (Iso–FITC and
Iso–PE). (g) Intracellular Gag expression for
BM–derived HPCs (Supplementary Fig. 2e) infected with HIV 89.6 and
cultured in CC110 cocktail. On day 7, the cells were divided either into
CC110 cocktail or GM–CSF–TNF–α. Asterisks
indicate Gag reactivity < mock treated cells. (h)
Graphical representation of the experiment depicted in part
(g).
We found similar numbers of integrated genomes plus or minus PMA
(Fig. 4b), indicating that
PMA–induced gene expression was not due to effects on integration.
Consistent with these results, the integrase inhibitor raltegravir blocked
initial infection but not PMA–induced gene expression (Supplementary Fig.
5). Similar results were obtained using
HXB–ePLAPenv89.6, albeit with lower infection rates
(Fig. 4c).Using wild type HIV–89.6 (Fig.
1b), we infected purified BM–derived HPCs (98%
CD34+, Supplementary Fig. 2d) and cultured them plus or minus
GM–CSF and TNF–α to induce myeloid differentiation
10.
GM–CSF–TNF–α–treatment of infected HPCs
resulted in rapid release of HIV into the culture supernatant (Fig. 4d). In contrast, BMMCs
immunodepleted for CD34+ cells did not release HIV (Fig 4d) and rapidly died (Supplementary Fig 4 b, c, d
and f). Flow cytometric analysis of the cells confirmed that
GM–CSF–TNF–α stimulated intracellular HIV Gag
expression (Fig. 4e) and that cells
cultured in GM–CSF–TNF–αacquired myeloid markers
(CD83+) (Fig. 4f).To assess the stability of latent HIV in HPCs, we infected
CD34+ BM–derived HPCs (99% pure, Supplementary Fig.
2e) with wild type 89.6. After 7 d, when the culture was uniformly
Gag–negative, GM–CSF–TNF–α was added to
half the culture. GM-CSF-TNF-α resulted in a resurgence of HIV gene
expression compared with the untreated culture (Fig 4g, h). 89.6 is a dual tropic HIV that
can utilize both CCR5 and CXCR4 to enter cells. Similar results were
obtained with a wild type virus that only uses CXCR4 although, as expected,
there was less viral spread in the differentiated myeloid cells (Supplementary Fig.
6b). Spread of infection in the culture was inhibited by
antiretrovirals and supernatant from infected cells could be used to infect
T cell lines (Supplementary Fig. 6).
Direct detection of latency
To detect latent infection in situ without inducing
changes in the infected cells, we developed a novel latency reporter virus
[89.6–ΔE–SF–GFP (Fig. 1c)] that expresses GFP independently of the HIV LTR.
Infection of T cells with
89.6–ΔE–SF–GFPenv89.6
yields some cells expressing Gag and others expressing only GFP (Fig. 5a). To confirm that
GFP+Gag− cells were latently infected, we
demonstrated that CD4 downmodulation, which occurs only when HIV Nef, Vpu or
Env is expressed, 11 occurred in
Gag+ but not GFP+Gag− cells
(Fig. 5a). In
contrast, when cells were infected with a virus that expressed GFP from the
HIV LTR (89.6–ΔE–IRES–GFP, Fig. 1g), GFP–expressing cells downmodulated CD4
(Fig. 5a). Similar results were
obtained using peripheral blood mononuclear cells (PBMCs) infected with
89.6ΔE–SF–GFPenv89.6
(Fig. 5b). Moreover, PMA and
ionomycin treatment of Jurkat cells infected with the reporter virus
increased Gag+ cell frequency and reduced
GFP+Gag− cell frequency (Fig. 5c).
Figure 5
Active and latent infection in T cells and HPCs. (a) Gag, GFP
and CD4 expression 7 d after infection in CEM–SS cells infected with
89.6–ΔE–SF–GFPenv89.6
or
89.6–ΔE–IRES–GFPenv89.6.
Histogram shading corresponds to cell gate. (b) Flow cytometric
analysis of PHA–activated PBMC infected with
89.6–ΔE–SF–GFPenv89.6
for 48 h. The histogram is shaded to match the gated cells. In the left
panel, the isotype control is shown in gray. (c) Flow
cytometric analysis of Jurkat cells infected with
89.6–ΔE–SF–GFPenv89.6
for 7 d, then split into PMA and ionomycin or DMSO control for 48 h.
(d) Flow cytometric analysis of UCB–derived
CD34+ HPCs infected with
89.6–ΔE–SF–GFPenv89.6
for 3 d. (e) Time course analysis of Gag+ and
Gag− GFP+ UCB–derived
CD34+ HPCs infected as above and cultured in CC110.
(f) Flow cytometric analysis of UCB–derived
CD34+ HPCs infected as above and cultured 3 d in CC110
medium. Gag+ cells and Gag−GFP+
cells were gated on the left plot and overlaid (black dots) on plots of CD34
vs. Lin (middle panels) or CD38 plots (right panels). The grey background
shows the total population.
We observed separate populations of Gag+ and
GFP+ cells in UCB–derived CD34+ HPCs
infected with the latency reporter virus, indicating that active and latent
infection occurred in this cell type (Fig.
5d). In culture, the Gag+ cells were rapidly lost
whereas the GFP+Gag−cells persisted at least 20
d (Fig. 5e, Supplementary Fig
1d). Analysis of these cells revealed that many had a cell surface
phenotype consistent with primitive HPCs
(CD34+Lin− or
CD34+CD38−)(Fig. 5f).
CD34+ cells from donors with HIV are Gag+
We obtained samples from HIV–infected people (Supplementary Table 1)
and found that we could detect Gag+CD34+ cells in three of
seven freshly isolated samples (Supplementary Table 1, Fig.
6a, bottom right panel). When the cells were cultured in
GM–CSF–TNF–α, Gag expression could be detected in
samples from all seven donors (Fig. 6b,c).
In contrast, donor BMMCs specifically depleted of CD34+ cells did not
express Gag after culturing (Fig. 6c, d).
The addition of the anti–HIV drug raltegravir [which inhibits new
in vitro infection in T cells (Supplementary Fig. 7)]
partially suppressed the induction of Gag+ cells (Fig 6c. d), confirming that a
component of the infection we observed was from viral spread. Similar results
were also obtained from a donor (number seven) who had undetectable viral loads
for 2 years (Supplementary
Table 1, Fig. 6e).
Figure 6
Active and inducible infection in HPCs from HIV+ people.
(a) HIV–1 Gag expression in freshly isolated
adherence–depleted
Lin−CD34+CD133+ BMMCs. The
middle panel shows background staining using an isotype control for the Gag
antibody only. (b) CD34 and intracellular Gag expression in
CD34+ cells stained immediately or after culturing (14 d).
Control shows background staining with an isotype control antibody.
(c) Gag expression before and after culturing in
GM–CSF–TNF–α plus or minus raltegravir for
donors 1-6. (d) Summary graph of Gag induction plus or minus
raltegravir. Fold induction = (% Gag+ in cultured cells) ÷
(initial % Gag+)]. Mean ± sd is shown. (e)
Intracellular Gag expression in Donor 7 CD34+ or
CD34–immunodepleted BMMCs cultured as described in c.
[GM (GM–CSF–TNF–α; GMR
(GM–CSF–TNF–α plus raltegravir)].
(f) Real–time PCR of HIV genomes
ng−1 DNA isolated from fresh CD34+ or
immunodepleted BMMCs. Mean ± sd is shown, n = 3.
(g) Real–time PCR of HIV genomes from donor
CD34+ or immunodepleted cells. The limit of detection was
approximately one HIV genome per 10,000 cells. Means ± sd,
n = two independent experiments with three replicates
each.
CD34+ cells from HIV+ donors with undetectable viral
loads contain HIV genomic DNA
Using a real–time PCR assay for integrated HIV DNA, we detected
viral genomes in freshly isolated CD34+ cells from four of nine
donors with undetectable viral loads on HAART for more than 6 months (44%)
(Fig 6f, g). In these donors, 40 (donor
7), 3.1 (donor 12), 39 (donor 14), and 2.5 (donor 15) HIV genomes per 10,000
CD34+ cells were detected. We detected HIV genomes in BMMCs
immunodepleted of CD34+ cells only for donor 12, for whom 1.2 HIV
genomes per 10,000 CD34− cells were detected. The limit of
detection for this assay varied by donor, but was approximately 1 genome per
10,000 cells due to the limited number of CD34+ cells obtained from
each donor. Thus, it is likely that the proportion of donors in which we
detected HIV genomes underestimates the percentage of HIV+,
HAART–treated individuals harboring integrated HIV genomes in
CD34+ cells.
DISCUSSION
Long–lived cellular reservoirs of latent HIV genomes are a critical
obstacle to viral eradication. Here, we demonstrate that HIV can infect
hematopoietic progenitor cells in vivo and in
vitro to cause an active, cytotoxic infection as well as a latent
infection that can be induced to active infection by cytokine treatment.Our finding that HIV infects HPCs with an immature phenotype, has clear
ramifications for HIV disease because some of these cells may be long–lived
and could carry latent HIV for extended periods of time. While further studies are
needed to demonstrate that CD34+ stem cells per se are
infected, the detection of HIV genomes in HPCs isolated from people effectively
treated with HAART for more than 6 months confirms that HIV targets some
long–lived HPCs. One might expect these results to predict the presence of
identifiable proviral records in differentiated lineages that are known not to be
susceptible. However, we show that actively infected HPCs are rapidly killed.
Therefore, we expect latently infected HPCs will be killed by viral activation
shortly after differentiation is induced.Further studies are now needed to demonstrate that residual circulating
virus in individuals on HAART is derived in part from HPCs, as previously
demonstrated for resting memory T cells 2.
Additionally, studies examining the factors influencing HIV infection and latency in
CD34+ cells, as well as limiting dilution experiments to determine
the fraction of proviral genomes in these cells that can be reactivated, would
further our understanding of this viral reservoir.
Authors: M Majka; T Rozmyslowicz; B Lee; S L Murphy; Z Pietrzkowski; G N Gaulton; L Silberstein; M Z Ratajczak Journal: J Clin Invest Date: 1999-12 Impact factor: 14.808
Authors: K A Clouse; D Powell; I Washington; G Poli; K Strebel; W Farrar; P Barstad; J Kovacs; A S Fauci; T M Folks Journal: J Immunol Date: 1989-01-15 Impact factor: 5.422
Authors: T F Neal; H K Holland; C M Baum; F Villinger; A A Ansari; R Saral; J R Wingard; W H Fleming Journal: Blood Date: 1995-09-01 Impact factor: 22.113
Authors: Caroline E Mullis; Amy E Oliver; Leigh Anne Eller; David Guwatudde; Amy C Mueller; Michael A Eller; Hannah Kibuuka; Merlin Robb; Thomas C Quinn; Andrew D Redd Journal: AIDS Res Hum Retroviruses Date: 2012-02-02 Impact factor: 2.205
Authors: Christine M Durand; Gabriel Ghiaur; Janet D Siliciano; S Alireza Rabi; Evelyn E Eisele; Maria Salgado; Liang Shan; Jun F Lai; Hao Zhang; Joseph Margolick; Richard J Jones; Joel E Gallant; Richard F Ambinder; Robert F Siliciano Journal: J Infect Dis Date: 2012-01-24 Impact factor: 5.226